Degron Therapeutics
About Degron Therapeutics
Degron Therapeutics is developing a platform for the discovery of small molecule molecular glue degraders (MGDs) that target specific oncogenic proteins, utilizing a proprietary library of over 10,000 compounds and advanced screening methods. The company addresses the challenge of targeting previously undruggable proteins involved in cancer progression, aiming to enhance treatment efficacy and improve patient outcomes.
```xml <problem> Many cancer-driving proteins are considered "undruggable" by traditional methods, hindering the development of effective therapies for various cancers and other diseases. Existing molecular glue degraders (MGDs) have often been discovered serendipitously, and rational design has been challenging due to the complexity of the ternary structure formed by E3 ligase-MGD-target. </problem> <solution> Degron Therapeutics is developing a novel class of small molecule MGD drugs using its proprietary GlueXplorer™ platform to target previously undruggable proteins. The GlueXplorer™ platform incorporates a structurally differentiated glue library of over 10,000 compounds, multiple complementary screening and validation platforms, and large datasets for AI/Machine Learning insights. This approach enables the rational design and discovery of MGDs that induce the interaction between E3 ubiquitin ligases and target proteins, leading to targeted protein degradation. The company is building a pipeline of first-in-class MGDs for disease targets that have been historically difficult to drug. </solution> <features> - GlueXplorer™ platform with a structurally differentiated library of over 10,000 MGD compounds - Novel chemical cores differentiated from IMiDs to expand the range of addressable targets and improve IP protection - Multiple complementary screening platforms, including target-based, phenotypic, and proteomic screens - Large datasets of compound-induced proximity and degradation data for AI/ML-driven insights - Robust pipeline of first-in-class MGDs targeting previously undruggable proteins - Lead program DEG6498, a potent and orally bioavailable MGD targeting HuR (ELAVL1), with FDA IND clearance for clinical development in solid tumors </features> <target_audience> The primary target audience includes pharmaceutical companies and research institutions focused on developing novel cancer therapeutics and exploring targeted protein degradation strategies for previously undruggable targets. </target_audience> ```
What does Degron Therapeutics do?
Degron Therapeutics is developing a platform for the discovery of small molecule molecular glue degraders (MGDs) that target specific oncogenic proteins, utilizing a proprietary library of over 10,000 compounds and advanced screening methods. The company addresses the challenge of targeting previously undruggable proteins involved in cancer progression, aiming to enhance treatment efficacy and improve patient outcomes.
Where is Degron Therapeutics located?
Degron Therapeutics is based in Shanghai, China.
When was Degron Therapeutics founded?
Degron Therapeutics was founded in 2021.
- Location
- Shanghai, China
- Founded
- 2021
- Employees
- 17 employees